Onkologie und Ökonomie – wie frei sind wir wirklich in der Behandlung von Patient*innen?

Wörmann, Bernhard; Hecken, Josef; Steutel, Han; Tamm, Ingo; Ullmann, Andrew J.; Kappert-Gonther, Kirsten; Einsele, Hermann; Siess, M.; Wylegalla, Christian

doi:10.1159/000517496

Cited by 1 publication

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After ten years, the AMNOG legislation has generated savings accumulating to a total of EUR 14 bn for the health insurance funds. Savings of around EUR 6 bn were expected for 2021 alone (Wörmann et al ., 2021). Accordingly, every possible AMNOG reform is discussed controversial from the perspective of cost development.…”

Section: Discussionmentioning

confidence: 99%

“…The savings target of EUR 2 bn defined in the draft legislation was achieved or exceeded by EUR 2.65 bn from 2018 at the latest (Bundesanzeiger, 2010; Schwabe et al ., 2020). The long-term permanent average annual saving is estimated at EUR 3 bn (Wörmann et al ., 2021). International price differences for patent-protected drugs are often the result of nationally different healthcare systems with their different reimbursement regulations, as well as due to social and economic determinants (Wagner and McCarthy, 2004).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Ten years of German benefit assessment: price analysis for drugs with unproven additional benefit

Kleining,

Laufenberg,

Thrun

et al. 2023

HEPL

View full text Add to dashboard Cite

Introduction Since 2011, the prices for all new drugs in Germany are negotiated based on a benefit assessment. The purpose of this study was to analyze the price regulation of drugs with unproven additional benefit. Methods Benefit assessment procedures from 2011 to 2020 were reviewed and selected through AMNOG Monitor and Lauer Taxe. Negotiated annual therapy costs, the annual costs of the most cost-efficient appropriate comparative therapy (ACT) and the potential budget impact for 33 included procedures were calculated. Results 55% of the included drugs achieved a negotiated price higher than the most cost-efficient ACT, 3% were identified as equal and 42% showed lower negotiated prices. The potential savings exceeded expenditures by around EUR 523.5 m. After price flexibility was adopted by the legislator in 2017, the overall potential savings still outweighed the expenditures by around EUR 62 m. Conclusions Our analysis shows that making price negotiations more flexible by law does not undermine the fundamental aim of the AMNOG, which is to avoid additional expenditure without increased patient benefit. The regulation can thus fulfill the objective provided by the legislature of keeping drugs without proven additional benefits in the German healthcare system.

show abstract

Section: Discussionmentioning

confidence: 99%